Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies how well itacitinib works for the treatment of bronchiolitis
obliterans syndrome after donor hematopoietic cell transplant. Itacitinib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth.